Archives: Agenda

• Challenges of data silos and interoperability across research and clinical
• Strategies for creating a cohesive data ecosystem that supports translational research
• Case examples of successful data integration improving patient outcomes or accelerating drug development
• Predictive and prognostic biomarker discovery through advanced analytics.
• Regulatory and validation considerations for clinical implementation

• Future-facing models: What will define a ‘remarkable’ trial in the next decade?
• Leveraging adaptive and decentralized trial designs to improve flexibility and speed
• Empowering sites and CROs as partners to improve patient outcomes
• Strengthening communication to avoid misaligned expectations in the face of global disruptions
• Reducing costs and environmental impact while maintaining scientific integrity

• Japan’s pharmaceutical market transformation: addressing drug lag and drug loss
• Regulatory and ecosystem reforms accelerating drug development in Japan
• Key trends and organizations supporting pharmaceutical innovation
• Strategic insights into Japan’s pharmaceutical business landscape
• Japan as a gateway to expansion across the Asian pharmaceutical market

• Reframe patient centricity from “initiative” → “operating model”
• Patient centricity is no longer a differentiator
  → It is a baseline expectation from regulators, investors, and patients
• Yet most organizations still treat it as:
  • A set of tools
  • A functional workstream
  • Or a late-stage overlay

• Patient centricity only scales when it is embedded into how we select, contract, govern, and operate with vendors

• Outsourcing decisions shape: study design feasibility, site experience, patient burden, speed, quality, and retention
• If patient centricity is not designed into outsourcing, it will not survive execution

• Shared operational foundations across rare oncology and other rare diseases
• Rare oncology–specific differences you must plan for in conducting and outsourcing clinical research

• Building biomarker operations functions that align with organizational scale and strategy
• Optimizing vendor and central lab partnerships
• Integrating biomarker data across translational and clinical pipelines
• Preparing for the next evolution of biomarker-driven clinical trials

The last mile of patient recruitment—connecting interested patients to sites—often breaks down. This session explores how PRPs such as Trialbee’s Honey Platform™ strengthens that handoff through invisible, backend infrastructure that reduces missed connections and improves enrolment at scale.

• Where patient-to-site handoffs fail
• Why a single backend matters across studies and regions
• How the Honey Platform improves conversion without changing the patient experience